Jesse D. Riordan

University of Iowa — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index1.0kcitations76works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(17), RNA modifications and cancer(16), CRISPR and Genetic Engineering(11), MicroRNA in disease regulation(9), RNA Research and Splicing(9)

Publications76 total

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines
Gynecologic Oncology·2025
A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
Oncogene·2025Open Access
Integrated genomic approaches to characterize biologic responses to MEK inhibition and mechanisms of therapeutic resistance in low-grade serous ovarian cancer
Gynecologic Oncology·2025
BifurcatoR: A Framework for Revealing Clinically Actionable Signal in Variance Masquerading as Noise
2025Open Access
Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer
Journal of Clinical Investigation·2025Open Access
Comparison of Lysis and Amplification Methodologies for Optimal 16S rRNA Gene Profiling for Human and Mouse Microbiome Studies
International Journal of Molecular Sciences·2025Open Access
A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
2024· 1 citedOpen Access
Abstract 1998: ABCB1 promotes uveal melanoma cell resistance to FR900359 and identifies a tumor cell subpopulation with a distinct gene expression signature
Cancer Research·2024
Abstract A026: Identifying mechanisms to target in combination with trametinib to improve therapeutic efficacy in low-grade serous ovarian cancer
Cancer Research·2024
Single-cell genomics analysis reveals complex genetic interactions in an <i>in vivo</i> model of acquired BRAF inhibitor resistance
NAR Cancer·2024· 2 citedOpen Access
Characterization of genetic mechanisms of ovarian tumor progression using sleeping beauty mutagenesis in vivo (2296)
Gynecologic Oncology·2023Open Access
Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer (2282)
Gynecologic Oncology·2023Open Access
Understanding cancer drug resistance with Sleeping Beauty functional genomic screens: Application to MAPK inhibition in cutaneous melanoma
iScience·2023· 5 citedOpen Access
Supplementary Figures 9-10 from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
Supplementary Tables S1-6 from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
Data from Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
2023Open Access
Supplementary Figures S11-13 from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
Data from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
Data from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
Supplementary Figures S11-13 from &lt;i&gt;Sleeping Beauty&lt;/i&gt; Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Adam J. Dupuy(41), Joseph H. Nadeau(17), David A. Largaespada(15), Vincent W. Keng(14), Barbara R. Tschida(13), Lewis R. Roberts(12), Aaron L. Sarver(12), Timothy P. Kuka(11), Pauline J. Beckmann(11), Michael A. Linden(11), Khalid Amin(11), Nuri A. Temiz(11), Lindsey A. Lee(10), Carlos A. Tierrablanca(10), Robert Hullsiek(10), Wendy A. Hudson(10), Rachel A. Heuer(10), Ju Dong Yang(10), Jesse D. Riordan(10), Christopher S. Stipp(9)